DEA Cracks Down on Weird Ketamine Cousin, Schedules It Tight
Published Date: 1/20/2026
Proposed Rule
Summary
Starting February 19, 2026, 2-fluorodeschloroketamine (2-FDCK) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even possesses 2-FDCK, who will now face strict rules and possible penalties. The move helps keep this new drug off the streets while the government figures out the long-term plan.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
2‑FDCK Placed in Schedule I
Starting when the temporary order is published on or after February 19, 2026, 2‑fluorodeschloroketamine (2‑FDCK) — including its salts and isomers — will be listed in Schedule I of the Controlled Substances Act. That means people who manufacture, distribute, import, export, sell, or possess 2‑FDCK will be subject to the regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances.
Research & Instruction Restricted
Once the temporary Schedule I order is in effect (on or after February 19, 2026), research, instructional activities, and chemical analysis involving 2‑FDCK will be subject to the regulatory controls that govern Schedule I substances. Institutions, laboratories, instructors, and researchers handling or proposing to handle 2‑FDCK will need to comply with Schedule I requirements and will be subject to administrative, civil, and criminal sanctions if they do not.
Temporary Order Is Not Judicially Reviewable
The temporary scheduling order for 2‑FDCK will not be subject to judicial review while it remains in effect. The order will be issued under 21 U.S.C. 811(h) and will take effect on publication (on or after February 19, 2026) and remain for two years, with possible extension of one additional year.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-14286, Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
2026-14136, Barlow St-Clair Lynch, M.D.; Decision and Order
Dr. Barlow St-Clair Lynch from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14137, Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.
Previous / Next Documents
Previous: 2026-00934, Amendment of Class E Airspace; Covington, KY
The FAA wants to update the Class E airspace around Covington, KY because a key navigation beacon nearby is being shut down. This change helps keep flight rules safe and up to date for pilots flying with instruments. If you have thoughts, speak up by March 6, 2026—no costs or delays expected for travelers or airlines.
Next: 2026-00959, Amendments to Definitions and Related Provisions Under the Randolph-Sheppard Vending Facility Program; Withdrawal
The Department of Education has decided to cancel proposed changes to the Randolph-Sheppard Vending Facility Program rules, which would have updated key definitions like “vending machine” and added new ones. This affects blind vendors and state agencies who use these rules to run vending facilities. No new rules or costs will happen now, and the withdrawal is official as of January 20, 2026.